These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20524401)

  • 1. Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer.
    Zhuang L; Bai J; Huang H; Tang C; Yang J; Zhou B; Gong Y; Duanmu Z; Chen J
    Oncol Res; 2010; 18(9):437-44. PubMed ID: 20524401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
    Kalofonos HP; Aravantinos G; Kosmidis P; Papakostas P; Economopoulos T; Dimopoulos M; Skarlos D; Bamias A; Pectasides D; Chalkidou S; Karina M; Koutras A; Samantas E; Bacoyiannis C; Samelis GF; Basdanis G; Kalfarentzos F; Fountzilas G
    Ann Oncol; 2005 Jun; 16(6):869-77. PubMed ID: 15855226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
    Kalofonos HP; Papakostas P; Makatsoris T; Papamichael D; Vourli G; Xanthakis I; Aravantinos G; Papadimitriou C; Pentheroudakis G; Varthalitis I; Samelis G; Syrigos KN; Xiros N; Stavropoulos M; Kosmidis P; Christodoulou C; Linardou H; Skondra M; Pectasides D; Economopoulos T; Fountzilas G
    Anticancer Res; 2010 Oct; 30(10):4325-33. PubMed ID: 21036759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for advanced gastric cancer.
    Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
    Popov I; Milicević M; Radosević-Jelić Lj
    Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
    Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
    Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.
    Wasserman E; Sutherland W; Cvitkovic E
    Clin Colorectal Cancer; 2001 Nov; 1(3):149-53. PubMed ID: 12450427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
    Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
    Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA drug approval summaries: oxaliplatin.
    Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
    Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line systemic therapy for metastatic colorectal cancer.
    Mocellin S; Baretta Z; Roqué I Figuls M; Solà I; Martin-Richard M; Hallum S; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006875. PubMed ID: 28128439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer.
    Simpson D; Dunn C; Curran M; Goa KL
    Drugs; 2003; 63(19):2127-56. PubMed ID: 12962525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
    Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
    Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
    Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
    Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
    Wulaningsih W; Wardhana A; Watkins J; Yoshuantari N; Repana D; Van Hemelrijck M
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008593. PubMed ID: 26869023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
    Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
    Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
    Fisher MD
    Clin Colorectal Cancer; 2001 Aug; 1(2):85-6. PubMed ID: 12445365
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.